Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More
Xconomy
JULY 1, 2016
To boost the initiative, which aims to speed the pace of cancer research, FDA said it would consolidate its cancer review divisions under the Oncology Center of Excellence. Analysts wondered if the Tesaro news would push Medivation’s acquisition price higher. PureTech also bucked the Brexit fallout this week.
Let's personalize your content